Study . | Study Type . | N . | With Diabetes, % . | With CLTI, %* . | With Diabetes, n . | Without Diabetes, n . | Major Outcomes . | |
---|---|---|---|---|---|---|---|---|
Ballotta et al., 2014 (49) | Retrospective | 1,310 | 49 | 100 | 643 | 667 | AFS 5 y 45.5 vs. 51% (P = 0.19) | OS 5 y 51 vs. 57% (P = 0.41) |
Wölfle et al., 2003 (50) | Retrospective | 211 | 45 | 100 | 94 | 117 | FF-amputation 1 y 85 vs. 83% (P = 0.76) | Mortality 1 y 22 vs. 5% (P <0.01) |
AhChong et al., 2004 (51) | Prospective | 265 | 66 | 100 | 176 | 89 | FF-amputation 5 y 78 vs. 81% (P = 0.79) | OS 5 y 33 vs. 43% (P = 0.03) |
Calle-Pascual et al., 2001 (52) | Prospective | 481 | 36 | — | 174 | 307 | FF-amputation 3 y Fem-pop 49.2 vs. 89.7% (P <0.01) Fem-distal 73.5 vs. 95.2% (P <0.01) | OS 3 y Fem-pop 97.2 vs. 90.3% (P NR) Fem-distal 82.1 vs. 96.3% (P <0.05) |
Feinglass et al., 2001 (53) | Prospective | 4,288 | 40 | 63 | 1,711 | 2,577 | AFS 5 y for patients with diabetes RR 1.4 (P <0.01) | AFS 5 y for patients with CLTI RR 1.2 (P <0.01) |
Singh et al., 2008 (54) | Prospective | 14,788 | 44 | — | 6,550 | 8,238 | Graft failure 30 d OR 0.72 (95% CI 0.58–0.89) | — |
Study . | Study Type . | N . | With Diabetes, % . | With CLTI, %* . | With Diabetes, n . | Without Diabetes, n . | Major Outcomes . | |
---|---|---|---|---|---|---|---|---|
Ballotta et al., 2014 (49) | Retrospective | 1,310 | 49 | 100 | 643 | 667 | AFS 5 y 45.5 vs. 51% (P = 0.19) | OS 5 y 51 vs. 57% (P = 0.41) |
Wölfle et al., 2003 (50) | Retrospective | 211 | 45 | 100 | 94 | 117 | FF-amputation 1 y 85 vs. 83% (P = 0.76) | Mortality 1 y 22 vs. 5% (P <0.01) |
AhChong et al., 2004 (51) | Prospective | 265 | 66 | 100 | 176 | 89 | FF-amputation 5 y 78 vs. 81% (P = 0.79) | OS 5 y 33 vs. 43% (P = 0.03) |
Calle-Pascual et al., 2001 (52) | Prospective | 481 | 36 | — | 174 | 307 | FF-amputation 3 y Fem-pop 49.2 vs. 89.7% (P <0.01) Fem-distal 73.5 vs. 95.2% (P <0.01) | OS 3 y Fem-pop 97.2 vs. 90.3% (P NR) Fem-distal 82.1 vs. 96.3% (P <0.05) |
Feinglass et al., 2001 (53) | Prospective | 4,288 | 40 | 63 | 1,711 | 2,577 | AFS 5 y for patients with diabetes RR 1.4 (P <0.01) | AFS 5 y for patients with CLTI RR 1.2 (P <0.01) |
Singh et al., 2008 (54) | Prospective | 14,788 | 44 | — | 6,550 | 8,238 | Graft failure 30 d OR 0.72 (95% CI 0.58–0.89) | — |
CLTI includes Rutherford classes 4–6 and Fontaine stages III–IV. d, day(s); Fem-distal, femoral to tibial, peroneal, or pedal bypass; Fem-pop, femoral to popliteal artery bypass; FF-amputation, freedom from amputation; m, months(s); NR, not reported; OS, overall survival; RR, relative risk; y, year(s).